Elevated protein kinase C b II (PKCb II ) expression develops during heart failure and yet the role of this isoform in modulating contractile function remains controversial. The present study examines the impact of agonist-induced PKCb II activation on contractile function in adult cardiac myocytes. Diminished contractile function develops in response to low dose phenylephrine (PHE, 100 nM) in controls, while function is preserved in response to PHE in PKCb II -expressing myocytes. PHE also caused PKCb II translocation and a punctate distribution pattern in myocytes expressing this isoform. The preserved contractile function and translocation responses to PHE are blocked by the inhibitor, LY379196 (30 nM) in PKCb II -expressing myocytes. Further analysis showed downstream protein kinase D (PKD) phosphorylation and phosphatase activation are associated with the LY379196-sensitive contractile response. PHE also triggered a complex pattern of end-target phosphorylation in PKCb II -expressing myocytes. These patterns are consistent with bifurcated activation of downstream signaling activity by PKCb II .
C lassical PKC up-regulation has been linked to human and animal models of heart failure for over a decade [1] [2] [3] . Cardiac dysfunction is associated with up-regulation of PKCa, PKCb I and/or PKCb II classical isoforms in response to pressure overload, ischemia, and inherited mutations 1, [4] [5] [6] . Under physiological conditions, PKCa is the major classical isoform expressed in adult mammalian hearts and it negatively modulates contractile function [7] [8] [9] . In mouse models, up-regulation of PKCa targets phosphorylation of inhibitor 1 (I-1), which then activates protein phosphatase I (PP1) activity, and in turn de-phosphorylates proteins such as phospholamban to diminish cardiac performance 10 . While there is substantial work devoted to understanding the role played by up-regulation of PKCb II during heart failure 2, [11] [12] [13] [14] [15] , the contribution of this isozyme to cardiac dysfunction and heart failure remains controversial.
Genetic models often provide insight into the role played by a specific kinase, but this has not been the case for PKCb II . Cardiac specific transgenic expression of wildtype PKCb II produced a loss of function phenotype 3, 15 , while inducible, cardiac-specific expression of constitutively active PKCb II improved contractile function 12 . More recently, pharmacologic treatments targeting PKCb as well as work in knockout models produced equally divergent ideas about the role of PKCb II during heart failure 5, 7, 14 . An integrative approach utilizing animal models is ultimately necessary to understand the role of kinases such as PKCb II in complex disease states, such as heart failure. However, studies in isolated myocytes may provide important insights into the role PKCb II plays in modulating contractile function and help resolve the controversy about the impact of PKCb II on myocyte contractile function.
In a recent report, up-regulated wildtype PKCb II was localized in a peri-nuclear distribution pattern under basal conditions and produced diminished contractile function within 2 days after gene transfer 16 . This decrease in function was associated with alterations in Ca 21 handling and a complex phosphorylation response in downstream Ca 21 handling and myofilament proteins. The present study extends this work to determine whether known PKC agonists activate and re-distribute PKCb II and change contractile function after vector-mediated PKCb II gene transfer and expression in isolated rat cardiac myocytes. The divergent phenotypic responses reported in different genetic animal models led to the hypothesis that basal and agonist stimulation may produce different PKCb II localization patterns and functional responses in adult myocytes. The present study focuses on the contractile function response to low doses of phenylephrine (PHE) to initially test this idea. In addition, the functional responses to moderate PHE doses, as well as phorbol 12-myristate 13-acetate (PMA), and endothelin-1 (ET-1) also are examined in this study. In contrast to the recently reported decrease in basal function 16 , agonistmediated activation is anticipated to enhance function in myocytes. This prediction is based on the functional improvements reported in mice expressing an inducible, constitutively active PKCb II 12 . Downstream signaling also is examined in parallel experiments to determine whether changes in target protein phosphorylation levels are associated with the functional response. The results indicate PKCb II activation by low dose PHE preserves myocyte contractile function, and produces a complex signaling response. A bifurcated downstream signaling pathway may help explain this complex signaling pathway in animal models.
Results
Experiments in this study examined the influence of PKCb II upregulation on agonist-mediated contractile function in cardiac myocytes. These functional studies were performed with adult rat cardiac myocytes 2 days after gene transfer, which is a time point when PKCb II up-regulation ( Fig. 1A ) was similar to the increase observed in failing human hearts 16 . The reduction in basal shortening associated with elevated PKCb II expression prior to agonist delivery ( Fig. 2A ) also was consistent with earlier results
.
Agonist-induced contractile function response. The contractile function response to 100 nM PHE was examined in control, PKCb II -, and PKCbDN-expressing myocytes to determine whether agonist-activation of PKCb II produces a specific functional response. During 15 min perfusion with PHE, the amplitude and rates of shortening and re-lengthening were preserved and/or slightly increased in PKCb II -expressing myocytes (Fig. 1B, 2B,C) . In contrast, the shortening amplitude decreased and the rates of shortening and re-lengthening slowed in control and PKCbDNexpressing myocytes. Addition of the PKCb inhibitor, LY379196 (LY) to PKCb II -expressing myoyctes restored PHE-induced decreases in contractile function, without influencing the responses of control or PKCbDN-expressing myocytes (Fig. 1B,2D ). This preservation of contractile function in response to PHE also was observed 3 days after gene transfer in PKCb II -expressing myocytes (Fig. 2E ). However, a differential response between control and PKCb II -expressing myocytes was not detected with 1 mM PHE (Fig. 3B ,C) or with PMA (50 nM; Fig. 3D ,E).
PHE-mediated PKCb II phoshorylation, localization and distribution. Phosphorylation and localization of PKCb II were examined to begin analyzing events contributing to the divergent functional response to 100 nM PHE. In control myocytes, PKC aThr638/b641 phosphorylation increased in response to PHE (Fig. 4A) , presumably due to increases in PKCa phosphorylation. In myocytes expressing PKCb II , the enhanced phosphorylation of classical PKCs detected under basal conditions 16 is not further increased by 100 nM PHE (Fig. 4A) . The relative contribution of phosphorylated PKCa versus b II during the PHE response remains unclear based on these results.
In addition, classical PKC phosphorylation in response to agonists is linked to kinase activation and translocation 17 . Thus, immunohistochemical (IHC) labeling and fractionation were used to determine whether 100 nM PHE induces PKCb II translocation. Treatment with 100 nM PHE caused the basal, peri-nuclear distribution of PKCb II 16 to transition to a striated pattern within 10 min of incubating myocytes in PHE (Fig. 4B ). This PHE-induced shift in PKCb II localization is similar to the striated distribution of a-actinin in the myofilament, and indeed these patterns overlapped in merged images. On close examination, the striated PKCb II fluorescence is more uneven or punctate than the a-actinin pattern. This pattern resembles the more punctate t-tubule distribution of transporters such as the Na 1 /Ca 21 exchanger 18 (NCX). The LY antagonist prevented the PHE-induced translocation, and the PKCb II distribution pattern remained similar to the peri-nuclear pattern observed under basal conditions (Fig. 4C) . The PKCb II distribution pattern in response to PHE also was studied after fractionation. Most PKCb II resided in the cytosol under basal conditions. This isoform transitioned into the myofilament fraction in response to PHE and LY attenuated this translocation (Fig. 4D) . While the membrane fraction is enriched in sarcolemmal proteins, t-tubule and junctional sarcoplasmic reticulum proteins also are found in the myofilament fraction 19 . PKCb II also tended to move into the membrane fraction during the PHE response, although the increase and inhibition by LY were not statistically significant. Overall, the IHC and fractionation studies indicate low dose PHE activates PKCb II translocation over the same time interval as the PKCb-specific functional response. 16 . CaMKIId and PKD phosphorylation were studied here to determine whether PKCb II also targets these downstream kinases during the low dose PHE response. PHE did not influence CaMKIId phosphorylation in controls and PKCbDN-expressing myocytes, and did not further enhance the phosphorylation of this kinase observed under basal conditions in PKCb II -expressing myocytes (Fig. 5A ). The comparable level of CaMKIId phosphorylation under basal conditions and in response to PHE for controls and PKCbDN-expressing myocytes is in agreement with our earlier work 16 . As reported previously, addition of LY also did not change pCaMKIId phosphorylation in response to PHE in PKCb II -expressing myocytes (results not shown). These results indicate this low dose PHE does not alter PKCb II targeting of CamKIId. However, addition of the phosphatase inhibitor, calyculin A (calA) along with PHE further increased CamKIId phosphorylation compared to PHE alone in myocytes expressing PKCb II (Fig. 5A ), which was attenuated by LY (Supp Figure 1A) . In contrast, CaMKIId phosphorylation remained nearly undetectable in response to calA and LY in controls and PKCbDN-expressing myocytes. These results suggest PKCb II activation by PHE accelerates CaMKIId phosphorylation turnover during the PHE response.
In contrast to CamKIId, PKD phosphorylation increased in response to low dose PHE in controls and myocytes expressing PKCb II or PKCbDN (Fig. 5B) . Myocytes expressing PKCb II developed the highest levels of PKD phosphorylation during the PHE response, and this increase was attenuated by LY (Fig. 5C ). In contrast, the enhanced PKD phosphorylation produced by 100 nM PHE was not changed by the inhibitor in control and PKCbDN-expressing myocytes. To determine whether PHE influences phosphorylation turnover on PKD, experiments were carried out in the presence of the calA phosphatase inhibitor and with the protein kinase A (PKA) inhibitor, PKI. PKA activation of phosphodiesterases could influence phosphorylation turnover 20 , but PKI inhibition of PKA did not change the PHE-mediated enhancement of PKD phosphorylation (Fig. 5D) . Addition of the phosphatase inhibitor calA along with PHE also produced a comparable level of PKD phosphorylation as PHE plus PKI in all 3 groups (results not shown). However, PKD phosphorylation was partially attenuated when LY was added along with PHE plus calA in PKCb II -expressing myocytes. The addition of LY did not change the response to PHE plus calA in controls or PKCbDN-expressing myocytes. This attenuated PKD phosphorylation response to PHE in PKCb II -expressing myocytes also resulted in no difference in PKD phosphorylation compared to PKCbDNexpressing and control myocytes (Fig. 5D) . Together, these studies show low dose PHE causes PKCb II to phosphorylate and presumably activate PKD, which could contribute to the divergent functional responses observed in PKCb II versus control myocytes.
Western analysis of myofilament and Ca 21 cycling protein targets. Our work then focused on potential myofilament protein targets for the PKCb II -dependent component of the PHE response based on the temporal association between myocyte contractile function, striated PKCb II localization, and downstream PKD phosphorylation in PKCb II -expressing myocytes. In 32 P radiolabeling experiments, PHE increased myosin light chain 2 (MLC 2 ), cTnI, and cMyBP-C phosphorylation above basal levels in PKCb II -expressing myocytes compared to controls, and LY attenuated these increases without influencing phosphorylation in control myocytes (Fig. 6A ). Phosphorylation of cTnI and cMyBP-C also is enhanced in PKCb IIexpressing myocytes under basal conditions (Fig. 6A, ref. 16), and both PKC and PKD target these proteins 21, 22 . Further analysis of the PKD-responsive residues on cTnI (e.g. Ser23/24; Fig. 6 ) and cMyBP-C (Ser302; Fig. 7 ) in addition to the cMyBP-C Ser273 and Ser282 sites were examined with phospho-specific antibodies. Western blot analysis indicated PHE had little influence on cTnI Ser23/24 phosphorylation in control myocytes, and phosphorylation of these residues in PKCb II -expressing myocytes was similar to controls during low dose PHE (Fig. 6B) . The increased cTnI phosphorylation detected in PKCb II -expressing myocytes during the low dose PHE response in the radiolabeling experiment and lack of change detected at Ser23/24 could indicate alternate residues on cTnI are phosphorylated by the PKCb II pathway. The more likely explanation is the presence of a phosphatase inhibitor in radiolabeling studies (Fig. 6A) but not in the Western analysis (Fig. 6B ). This later possibility was confirmed with the addition of calA during the PHE response, which resulted in elevated cTnISer23/24 phosphorylation in PKCb II -expressing myocytes (Fig. 6C,E ). An unexpected finding was the further enhancement of PHE-induced cTnISer23/ 24 phosphorylation with the addition of LY in myocytes expressing PKCb II compared to controls or PKCbDN-expressing myocytes (Fig. 6D,E) . The influence of LY is consistent with PKCb II targeting both phosphatase and PKD activity, and low dose PHE causing PKCb II to target phosphatase over kinase activation in the absence of a phosphatase inhibitor. In studies with PMA, the cTnISer23/24 phosphorylation response to this PKC activator was similar in control and PKCb II -expressing myocytes (Fig. 6F) .
Myocytes expressing PKCb II also develop enhanced cMyBP-C phosphorylation 16 , and PHE produced a unique pattern of Ser273, Ser282 and Ser302 phosphorylation in these myocytes (Fig. 7) . Cardiac MyBP-C Ser282 phosphorylation (p282) tended to decrease with PHE in PKCb II -expressing myocytes relative to controls and LY attenuated this change (Fig. 7A,B) . The trend toward decreased pSer282 in response to PHE also was attenuated when calyculin A was included with PHE (Supp Figure 1B) . These trends are consistent with dual downstream kinase and phosphatase modulation by PKCb II activation during the PHE response. In contrast, cMyBP-C Ser273 and Ser302 phosphorylation were not substantially changed by PHE in control, PKCb II or PKCbDN-expressing myocytes compared to basal values. Phosphorylation of cMyBP-C Ser273 was not detected under basal conditions or in response to PHE in any of the 3 myocyte groups (results not shown). The enhanced basal phosphorylation of Ser302 in PKCb II -expressing myocytes ( Fig. 7A ; ref. 16) was not further elevated during the PHE response in the presence or absence of LY (Fig. 7A,B) . PHE also had little influence on Ser273 and Ser302 phosphorylation in the presence of calA (Supp Figure 1B) . Taken together, low dose PHE does not uniformly increase phosphorylation levels at specific sites on these myofilament proteins, although there is evidence PHE accelerates phosphorylation turnover, at least at some sites (cTnISer23/24 and cMyBP-CSer282). While accelerated phosphorylation turnover in these myofilament proteins may not directly explain the maintenance of shortening during the PHE response in PKCb II -expressing myocytes (Fig. 2) , this observation also suggests it may be difficult to capture changes in phosphorylation level during an agonist response.
To determine whether a similar pattern of phosphorylation turnover develops in potential Ca 21 cycling targets, our focus turned to phospholamban (PLB) which can be phosphorylated at Ser16 and Thr17 (Fig. 8A,B) . Low dose PHE tended to decrease PLB Ser16 phosphorylation (pSer16) in all 3 groups relative to the basal values 16 . The greatest decrease in PLB phosphorylation developed in PKCb IIexpressing myocytes, although this reduction was not significantly different from controls treated with PHE (Fig. 8A,B ) and disappeared at higher PHE concentrations (Supp Fig. 1C ). In contrast, PLB Thr17 phosphorylation (pThr17, Fig. 8A ) was similar to controls and PKCbDN-expressing myocytes after treatment with PHE. Phosphorylation of this residue remained comparable to basal values 16 in controls and PKCbDN-expressing myocytes treated with PHE, while PKCb II reduced basal PLB Thr17 phosphorylation compared to controls. Thus, PHE increased PLB Thr17 phosphorylation in PKCb II -expressing myocytes, such that these levels were comparable to controls. Addition of calA with PHE heightened phosphorylation of PLB pSer16 and pThr17 in all groups, although PKCb II -expressing myocytes developed the most dramatic increases (Fig. 8A,B) . PHE-mediated phosphorylation of these PLB residues in PKCb IIexpressing myocytes is similar to controls in the presence of LY (Fig. 8C ).
Discussion
Our results show PKCb II up-regulation improves cardiac myocyte contractile function relative to controls in response to low dose PHE (Figs. 1,2) . The same level of PKCb II up-regulation diminished basal contractile function in earlier work 16 . This ability of PKCb II to differentially modulate contractile function is consistent with the anticipated role of PKCs to act as a cellular mini-processor 17 . Spatial distribution appears to be one component of this processor, as diminished basal function correlates with peri-nuclear PKCb II localization 16 , while a striated distribution pattern coincides with the PHE-induced response (Fig. 4) . Based on our results, downstream kinase and phosphatase activation (Fig. 5   16 ,) and accelerated phosphorylation turnover in multiple end-target proteins (Figs. 6-8 ) also contribute to the PKCb II signaling processor. Further work is now needed to evaluate the level of accelerated phosphorylation turnover in myofilament and Ca 21 cycling end-target proteins after PKCb II up-regulation and identify whether multiple downstream kinases and phosphatases contribute to turnover on end targets.
Our results and earlier work show functional responses produced following classical PKC up-regulation are explained by changes in Ca 21 cycling and/or myofilament protein phosphorylation 10, 16 . The increased PKCb phosphorylation (Fig. 4) associated with the reduced shortening response to low dose PHE in control myocytes (Figs. 1,2) is consistent with the stimulation of protein phosphatase 1 (PP1) by this PKC isoform, which acts to decrease downstream PLB Ser16 phosphorylation 10 . The maintenance of contractile function in response to low dose PHE in myocytes expressing PKCb II activation (Figs. 1,2 ) also is associated with evidence showing both myofilament and Ca 21 cycling protein phosphorylation are targets for this isoform (Figs. 6-8 ). In our earlier work, PKCb II decreased contractile function and targeted the same proteins under basal conditions, and yet only the decrease in PLB Thr17 phosphorylation changed in a direction that could explain the diminished contractile function 16 . The restoration of PLB Thr17 phosphorylation toward basal control levels during the 100 nM PHE response (Fig. 8   16 ,) is consistent with this target working to maintain shortening amplitude (Fig. 1,2) . However, experiments with calA demonstrate PKCb II expression is associated with a consistent acceleration of phosphorylation turnover in multiple myofilament and Ca 21 cycling proteins during the 100 nM PHE response (Figs. 6-8) . While the phosphorylation state of a single residue, such as Thr17-PLB correlates with basal and PHEinduced changes in contractile function, the accelerated phosphorylation turnover may be the more important observation. Enhanced phosphorylation turnover could be an essential component of PKCb II signaling, by allowing small changes in the cellular microenvironment to rapidly modulate cardiac performance via shifts in the balance between kinase and phosphatase activity produced by PKCb II . The increased PKD phosphorylation (Fig. 5 ) and differences in end target phosphorylation observed with and without the phosphatase inhibitor (Figs. 6-8) provide initial evidence to support the idea of bifurcated activation of kinases and phosphatases by PKCb II . Parallel kinase and phosphatase activation also is consistent with complex patterns of target protein phosphorylation, as reported for basal 16 and agonist-stimulated conditions (Figs. 6-8 ). Stochastic computational models are often used to explain similar behavior in other signaling and enzyme pathways [23] [24] [25] . Bi-or multistable models predict bifurcated signaling as well as external noise amplification 23, 25 . Most importantly, models incorporating increased downstream kinase and phosphatase activity predict there are conditions when phosphorylation turnover is greatly enhanced, with little detected change in end-target phosphorylation. Thus, detected changes in target protein phosphorylation depend on large changes in phosphatase and/or kinase activity. The addition of a phosphatase inhibitor should dramatically influence end-target phosphorylation, which is clearly apparent in the response of PKCb II -expressing myocytes to low dose PHE (Figs. 6-8 ). Based on these results, a stochastic model utilizing parallel activation of downstream kinases and phosphatases 23 is predicted to provide insight into PKCb II miniprocessor function and downstream function in cardiac myocytes in future work.
One important prediction from this type of model is that PKCb II up-regulation stimulates ATP and energy utilization in an effort to modulate contractile function. In cardiac myocytes, this up-regulation of PKCb II may be beneficial for modulating cardiac performance during early, compensated cardiac dysfunction. The initial PKCb II up-regulation may increase contractile performance if phosphorylation turnover is accelerated in response to low neurohormone levels. However, chronic up-regulation of this isoform could further tax hearts experiencing cellular stress, and ultimately cause deterioration in myocardial energetics and impair pump performance.
Stochastic modeling also could provide insight into the seemingly paradoxical relationship between cardiac dysfunction and PKCb up-regulation reported in earlier work. PKCb II up-regulation is consistently reported during end-stage human heart failure 1, 16, 26 and in several animal models of heart failure 4, 27 . Diminished cardiac performance develops in transgenic mice expressing wildtype PKCb II 3, 15 , and yet inducible expression of constitutively active PKCb II enhances adult myocardium contractile function 12 . Enhanced phosphorylation turnover may develop in both mouse models, with downstream phosphatase activation favored in mice expressing wildtype PKCb II and a tilt toward downstream kinase activity in mice expressing the constitutively active PKCb II .
Discrepancies among genetic as well as other PKCb II -related animal models and pre-clinical studies with the PKCb inhibitor, ruboxistaurin indicate a model is needed to guide future work on PKCb II signaling in myocytes. For example, a PKCb II -specific inhibitor peptide proved to be functionally beneficial during chronic pressure overload in Dahl salt-sensitive rats 28 , while activated PKCb II was functionally protective in an ischemia reperfusion injury model 29 .
Other investigators using knockout mice also concluded PKCb provides a modest protective effect against pressure overload 14 . In contrast, ruboxistaurin treatment of animal models developing heart failure reduced PKCb expression and improved in vivo cardiac function 11, 27 . Recently, these cardiac performance improvements were attributed to inhibition of PKCa rather than PKCb 14 . However, the anticipated changes in downstream phosphorylation of end-target proteins which modulate contractile function and are targeted for phosphorylation by PKCa or b were not changed by ruboxistaurin treatment 30 . Future models are needed to explain these seemingly divergent results and the inability to capture changes in downstream target phosphorylation. A stochastic model incorporating the enhanced phosphorylation turnover detected here is a logical starting point.
Potential factors requiring further consideration in a future model include PKCb II localization and identification of alternative end targets. Our work shows PKCb modulates myofilament, Ca 21 cycling, and kinase phosphorylation. In addition, there is evidence PKCb II may target CaMKII (Fig. 5A, ref. 31 ), phospholemman 32 , ryanodine receptor 33 , other cTnI residues 34, 35 , Cav1.5, and NCX
36
. The current results also show dramatic PKCb II localization changes in response to low dose PHE (Fig. 4) compared to the basal state 16 . Both PKCb II trafficking and the possibility this isoform accelerates phosphorylation turnover in additional protein targets will need to be factored into future models.
In summary, our work shows PKCb II signaling negatively modulates contractile function under basal conditions and positively modulates this function in response to a low dose a-adrenergic agonist. Complex patterns of downstream target phosphorylation are associated with both basal and agonist-stimulated conditions. Testable models are needed to understand the relationship between the contractile function and end target phosphorylation responses. A stochastic model incorporating bifurcated signaling is discussed as a starting point for this work based on our current observations. Additional elements to explain PKCb II modulation of contractile function are likely to include alternative targets, trafficking, PKC isoform dominance, as well as PKC isoform feedback loops 17 . Future computational models are anticipated to provide insight into the PKCb II signaling pathway and pave the way for pre-clinical therapies.
Methods
Myocyte isolation and gene transfer. Adult rat cardiac myocytes were isolated, made Ca 21 -tolerant, and plated on laminin-coated coverslips in DMEM plus 5% FBS, penicillin (50 U/ml) and streptomycin (50 mg/ml; P/S) for 2 hours, as described earlier 16, 37 . Gene transfer of PKCb II or PKCbDN was carried out in serum-free DMEM plus P/S using recombinant adenoviral vectors (10 MOI) 37 for 1 hr followed by the addition of M199 plus P/S media. Electrical pacing of myocytes was initiated 24 hrs after plating in M199 media plus P/S, with media changes every 12 hrs 37 . Experiments with myocytes were performed 2 days after gene transfer unless otherwise noted. All animal procedures utilized for these studies followed the guidelines of and were approved by the University Committee on Use and Care of Animals at the University of Michigan.
Contractile function measurements. Sarcomere shortening in isolated myocytes was measured with a video-based microscope platform (Ionoptix, Beverly, MA) in a 37uC temperature-controlled chamber perfused with M199 with or without agonist 38, 39 . Resting sarcomere length, peak shortening amplitude, shortening and re-lengthening rates (mm/sec), time to peak (TTP), plus times to 25%, 50%, and 75% re-lengthening (TTR 25% , TTR 50% , TTR 75% ) were measured from signal averaged recordings of myocytes. Contractile function was measured under basal conditions and in response to the a 1 agonist, phenylephrine (PHE; 0.1 and 1 mM), and to PMA (50 nM). The contribution of PKCb II to the PHE response was evaluated with and without the PKCb inhibitor, LY379196 (LY; 30 nM; kind gift of Dr. Chris Vlahos, Eli Lilly) 40, 41 .
Western analysis. Expression and phosphorylation of PKCb also were measured in myocytes 2 days after gene transfer. Myocytes were collected into sample buffer, proteins were separated using 12% SDS-PAGE, and then transferred onto PVDF membrane for all proteins studied, as described earlier 16, 37, 38 . PKCb II expression and phosphorylation levels were detected by Western analysis using enhanced chemiluminesence. For Western detection, membranes were incubated in primary antibodies directed to PKCb II (BD Biosciences, San Jose, CA) or phosphorylated PKCa/b (Cell Signaling Technology, Danvers, MA) followed by horseradish peroxidase-conjugated secondary antibodies and detected with film. Expression and phosphorylation of downstream targets also were analyzed by Western analysis. Primary antibodies directed to phospho-cTnISer23/24 (Cell Signaling), troponin I (Millipore), phospholamban (PLB), phosphoSer16-PLB (pSer16-PLB), phosphoThr17-PLB (pThr17-PLB), as well as expression and phosphorylation of cardiac myosin binding protein C (cMyBP-C), phospho-Ser273-, phospho-Ser282-, and phospho-Ser302-cMyBP-C, Ca 21 -calmodulin-dependent protein kinase IId (CAMKIId), and protein kinase D (PKD) were utilized and detected as described in detail in earlier work 16 . After detection of phosphorylated PKCb, troponin I, PLB, cMyBP-C, CamKIId, and PKD, membranes were stripped and re-probed for total expression of the same protein with the exception of CamKIId, which was probed for actin. Films were scanned using a scanner (Microtek ScanMaker 4) with the resolution set at 600 dpi. Quantitative analysis of protein expression was carried out with Quantity One software and normalized to total expression of the same protein or actin.
Indirect immunofluorescence imaging. PKCb localization in myocytes was determined by immunohistochemical staining of paraformaldehyde-fixed cells 16, 38 . Cellular distribution of PKCb was determined using the same primary PKCb II antibody described under protein detection and a goat anti-mouse secondary antibody conjugated to fluorescein isothiocyanate (FITC, Invitrogen). The PKCb distribution in response to 10 min PHE (100 nM), or 10 min PHE plus LY379196 (30 nM) was analyzed in control and PKCb II -expressing myocytes. In a subset of myocytes, dual immunostaining with the PKCb antibody and a-actinin antibody (EA-53; 15500) was performed to determine whether PKCb II is distributed in a striated pattern similar to the myofilament z-band in response to 100 nM PHE (10 min). Primary antibody binding was detected with secondary antibodies conjugated to FITC-and Texas Red (TR), respectively. Myocytes immunostained for a-actinin and PKCb after treatment with PHE were imaged using a Fluoview 500 laser scanning confocal microscope (Olympus) without deconvolution. Images collected after treatment with PHE plus LY379196 were obtained with a Nikon Ti-U fluorescence microscope.
Fractionation studies. Cells were fractionated after a 10 min treatment under basal conditions in M199 containing the phosphatase inhibitor, calA (10 nM), or in M199 plus calA containing 100 nM PHE with or without 30 nM LY at 37uC. Then, myocytes were collected in ice-cold lysis buffer (20 mM Tris, pH 7.5, 2 mM EDTA, 2 mM EGTA, 250 mM sucrose, 6 mM b-mercaptoethanol, 48 mg/ml leupeptin, 5 mM pepstatin, 0.1 mM Na orthovanadate, and 50 mM NaF) and centrifuged at 1000 3 g for 10 min at 4uC, as described earlier 19, 42 . The supernatant was further fractionated for 1 hr at 100,000 3 g into a cytosol-enriched supernatant, and non-nuclear membrane enriched pellet 19, 42 . Ice cold sample buffer was added to each sub-fraction, then briefly sonicated, and then proteins separated on 12% SDS-PAGE gels, transferred to PVDF membranes, and analyzed for PKCb II expression.
Radiolabeling studies. Phosphorylation of downstream targets in response to 10 min PHE (100 nM) with and without LY (30 nM) was initially analyzed in radiolabeled myocytes 43 . Myocytes labeled with 32 P-orthophosphate (100 mCi) for 2 hrs at 37uC were transferred to un-labeled M199 media containing 10 nM calA (basal), or the same media with PHE (0.1 mM) with and without LY (30 nM) for 10 min. Phosphorylation was terminated in ice-cold relaxing solution (RS; 7 mM EGTA, 20 mM imidazole, 1 mM free Mg 21 , 14.5 mM creatine phosphate, and 4 mM MgATP with KCl added to yield an ionic strength of 180 mM, pH 7.00) and myocytes were collected into ice-cold sample buffer 16 . Proteins in each sample are separated on a 12% SDS-PAGE gel, and then the silver-(Ag) stained gel was dried overnight. Phosphorylation was analyzed using a Phosphor-imager (Bio-Rad, Hercules, CA), and radioactive bands were quantified after an overnight cassette exposure using Quantity One software (Bio-Rad, Hercules, CA). Contractile proteins were identified based on their migration relative to mw markers.
Statistical analysis. Quantitative results are expressed as mean 6 SEM, and an unpaired Student's t-test or one-way analysis of variance (ANOVA) and post-hoc Newman-Keuls tests are used to analyze myocyte contractile function. Quantitative analysis of protein expression and phosphorylation levels are compared using a oneor two-way ANOVA and post-hoc Newman-Keuls tests, with p , 0.05 considered statistically significant. Measurements of PKCb II expression and 32 P-labeled phosphor-images in fractionated myocytes are normalized to SDS-PAGE Ag-stained gels and values are expressed relative to controls.
